𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of famotidine in patients with cirrhosis and ascites

✍ Scribed by G. Vinçon; C. Baldit; P. Couzigou; F. Demotes-Mainard; L. Elouaer-Blanca; B. Bannwarth; B. Begaud

Publisher
Springer
Year
1992
Tongue
English
Weight
492 KB
Volume
43
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of paroxetine in patien
Pharmacokinetics of paroxetine in patients with cirrhosis
✍ K. Dalhoff; T. P. Almdal; K. Bjerrum; S. Keiding; H. Mengel; J. Lund 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 419 KB

In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20-30 mg paroxetine daily was adjusted to the reduction in liver function, as assessed by the galactose elimination capacit

Beta-blockers in patients with cirrhosis
Beta-blockers in patients with cirrhosis and refractory ascites
✍ Albillos Agustín; Zamora Javier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB 👁 2 views

We read with interest the reviews by Ghouri et al. 1 and Martinez et al. 2 Ghouri et al. analyzed the association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD) and concluded that although a diagnosis of NAFLD should prompt diabetes screening, it is insufficient for co

Torasemide in the treatment of patients
Torasemide in the treatment of patients with cirrhosis and ascites
✍ Paolo Gentilini; Giacomo Laffi; Giorgio La Villa; Vinicio Carloni; Marco Foschi; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 493 KB

The effects of torasemide (20 mg/day) and furosemide (50 mg/day), each given over 4 days, were compared in a randomized and crossover study carried out in seven patients with cirrhosis and tense ascites. Patients also received a low-sodium (40 mmol/day) diet and the aldosterone antagonist, potassium